Navigation Links
Concentric Medical Announces Product and Procedure Reimbursement as Well as Full Commercialization of the Merci Retriever® in Japan
Date:10/4/2010

MOUNTAIN VIEW, Calif., Oct. 4 /PRNewswire/ -- Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients, today announced that the Merci Retriever® has recently received both product and procedure reimbursement from the Japanese Ministry of Health, Labor and Welfare.  The Merci Retriever is a catheter-based medical device that physicians at stroke centers use to remove blood clots from the brains of patients suffering an ischemic stroke.

On May 4th, Concentric Medical announced the Shonin approval of the Merci Retriever®, Merci® Microcatheter, and Merci® Balloon Guide Catheter.  

Nobuyuki Sakai, M.D., D.M.Sc., Director, Neurosurgery & Stroke Center at Kobe City General Hospital said, "The Merci Retriever is quickly becoming a very meaningful treatment option for acute stroke patients in Japan.  The initial cases at leading stroke institutions since Shonin approval have been very successful.  Reimbursement for the Merci Retriever and the mechanical procedure are a critical part of making the Merci system available to all neurosurgeons, neurologists, and hospitals in Japan that treat acute stroke patients."

Century Medical, Inc. is the exclusive distribution partner for Concentric Medical in Japan.  The two companies worked together to obtain both Shonin approval and reimbursement for the Merci Retriever, which is the first device for clot removal for ischemic patients to be approved in Japan.

One of Concentric Medical's strategic objectives has been global expansion. The incidence of stroke and the mortality and disability associated with stroke are very significant issues for health care systems across the world.  Maria Sainz, President and CEO of Concentric Medical said, "We are honored to be the first to offer a device solution for stroke patients in Japan. Launching the Merci system in Japan is a very significant milestone and a great new opportunity for growth for our company.  With over 1,300 patients enrolled in clinical studies, we believe Merci has been proven to be a very effective tool in revascularizing stroke patients."

Akira Hoshino, President and CEO of Century Medical, Inc. said, "Century Medical is extremely excited to bring such a valuable and innovative therapy to Japan.  The reimbursement for both the Merci Retriever and procedure related to mechanical thrombectomy with the Merci Retriever are an essential part of the introduction of this new treatment.  Century Medical is committed to pioneering stroke treatment in Japan by working closely with physicians and hospitals to make the Merci Retriever widely available for Japanese stroke patients."

About Concentric MedicalConcentric Medical is located in Mountain View, California and is the global leader in the development of endovascular devices for revascularizing stroke patients.  The company manufactures and markets solutions for ischemic stroke: minimally invasive devices that are delivered into the brain to restore blood flow by removing blood clots that cause ischemic stroke.  Concentric Medical's devices are available in over 500 leading stroke centers around the world, and have been the subject of several clinical studies.  For more information about Concentric Medical, please visit www.concentric-medical.com.

About Acute Ischemic StrokeStroke is the third leading cause of death in the developed world and the leading cause of serious long-term disability. Ischemic stroke represents over 85% of strokes and occurs when a blockage or clot develops in one of the arteries supplying blood to the brain. In 2004 the FDA cleared Concentric Medical's Merci Retriever for use in stroke patients who are ineligible for IV-tPA or who fail to respond to IV-tPA therapy. This pioneering device created a departure from the historic method of caring for stroke patients and offered physicians and patients a long-awaited option for stroke intervention.

For more information about Concentric Medical, please visit www.concentric-medical.com.Media Contact: +1 650-938-2100strokeinfo@concentric-medical.com
'/>"/>

SOURCE Concentric Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Concentric Medical to Sponsor Randomized Trial
2. Concentric Medical and the Merci Retrieval System(R) Highlighted at the 2010 International Stroke Conference
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Globus Medical Raises $110 Million in Series E Financing Round
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Boston University Biomedical Engineers Find Chink in Bacterias Armor
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 23, 2017 Non-alcoholic steatohepataitis ... the various drugs being developed for the ... the drugs that are in various phases ... pipeline focuses on novel pharmacologic drugs & ... cell therapies, recombinant proteins and RNA-based therapeutics, ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an ... that it has acquired exclusive worldwide rights to ... innovative HDAC inhibitor targeting hematological and solid tumors. ... Phase 1 and 2 clinical trials of Abexinostat ... have already been completed, demonstrating that Abexinostat ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Disorder Drugs Price Analysis and Strategies - 2016" report to ... ... - 2016, provides drug pricing data and benchmarks in the global ... What are the key drugs marketed ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... With ProGlass Prism users now have the ability to simulate ... over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, ... ProGlass Prism users are given the tools and effects to generate a fractal ...
(Date:2/24/2017)... ... , ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 ... image mannequin art competition. Selected from 15 submissions from around the nation, the top ... 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This year, ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... which specializes in thought leadership , media relations, social media, content marketing ... that will be powered through Act-On, an intuitive marketing automation platform. , Rosica ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning ... Gran Fondo of Marin. For the second year in a row, cyclists will ... , “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... Gorce Country Club in Miami Beach to host its Swirl: Miami Wine Tasting ...
Breaking Medicine News(10 mins):